adjuvanted) clinical trials

CONCOMITANT ADMINISTRATION OF LICENSED VACCINES AGAINST COVID-19 AND FLU WITH OR WITHOUT MF59 ADJUVANT: A MULTI-CENTRE, RANDOMIZED, SINGLE-BLIND CLINICAL TRIAL TO ASSESS IMMUNOGENICITY IN ADULTS AGED 65 AND OVER

This study looks at giving COVID-19 and flu vaccines at the same time to people aged 65 and over. We want to see how well their bodies respond to both vaccines and if it's safe to have them together. This could make it easier for older adults to stay protected.

COVID-19 vaccine immunological studies in Finland

This study in Finland is looking at how well different COVID-19 vaccines protect people. It's especially interested in how strong our body's defence (antibodies) is six months after two vaccine doses, and how this works against current virus types.

Vaccination against respiratory syncytial virus in patients with inflammatory rheumatic diseases. The impact of anti-rheumatic treatments on the RSV immune response.

This study looks at how well RSV vaccines work in people with inflammatory rheumatic diseases. We want to see if their anti-rheumatic medicines affect how their body responds to the vaccine and creates protection against the RSV virus.

Phase IV multicenter immunogenicity and safety study of the Seqirus licensed zoonotic influenza vaccine (H5N8) in adults immunized with an H5N1/MF59 influenza vaccine, approximately 20 years before the trial, compared to H5 naive adult participants.

This study is looking at a new bird flu vaccine (H5N8) in adults. We want to see how well it helps your body fight off the virus, especially if you had a similar bird flu vaccine (H5N1) many years ago, compared to those who haven't had a bird flu vaccine before.

A Phase IV, open label, single arm trial to assess the safety and immunogenicity of BIMERVAX® LP.8.1 against SARS-CoV-2 variants.

This study is looking at a new COVID-19 vaccine, BIMERVAX LP.8.1, to see how safe it is and how well it helps your body fight off different types of the virus, especially Omicron. It's for people who've already had the vaccine (Phase IV).

Herpes zoster after recombinant herpes zoster vaccination - Immediate post-RHZ-vaccination evolution of CMI, HMI and lymphocyte count and typing.

This study looks at how Shingrix, a vaccine for shingles, changes your immune system right after you get the shot. Researchers want to see how your body's defence against the chickenpox virus reacts in the first three weeks after vaccination.

COPD-2VAX: Enhancing Protection Against Respiratory Infections Through AS01-Mediated Innate Immune Activation in High-Risk Patients

This study looks at how new vaccines for lung conditions and common infections work in people with COPD. It aims to see if these vaccines can help their body's defenses (immune system) fight off respiratory illnesses better.

Open-label, Multi-centre, Non-Inferiority study of safety and immunogenicity of BIMERVAX as heterologous booster for the prevention of coronavirus disease 2019 (COVID-19) in adolescents from 12 years to less than 18 years of age.

Prospective Randomized trial of Everolimus replacing MMF/MP Acid by the RECOVAC consortium to increase VACcine response in kidney transplant patients

A phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen, inactivated, adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19.

A Phase 2b, randomized, controlled, open-label study to evaluate the immune response and safety of the RSVPreF3 OA investigational vaccine in adults (≥18 years of age) when administered to lung and renal transplant recipients comparing 1 versus 2 doses and compared to healthy controls (≥50 years of age) receiving 1 dose

A Phase 3, open-label, randomized, controlled study to evaluate the immune response, safety and reactogenicity of RSVPreF3 OA investigational vaccine when co-administered with a COVID-19 mRNA vaccine (Omicron XBB.1.5) in adults aged 50 years and above.

A Phase 3b, open-label study to evaluate the non-inferiority of the immune response and to evaluate the safety of the RSVPreF3 OA investigational vaccine in adults 18-49 years of age at increased risk of respiratory syncytial virus disease, compared to older adults ≥60 years of age.

Temporal kinetics of antibody and cellular response markers and relative impact of revaccination in patients recovered from COVID-19 after treatment with monoclonal antibodies

A Phase 3, randomized, controlled, partially blind, immuno-bridging study to evaluate immunogenicity, reactogenicity, safety and the occurrence of RSV-associated respiratory tract illness after administration of a single dose of GSK’s RSVPreF3 OA investigational vaccine in adults aged 60 years and older.